Enhanced specific delivery and targeting of oncolytic Sindbis viral vectors by modulating vascular leakiness in tumor

Cancer Gene Therapy

Volumn 17, Issue 4, 2010, Pages 244-255

  Tseng, J C ^a   Granot, T ^a   Digiacomo, V ^a   Levin, B ^a   Meruelo, D ^a  

^a NEW YORK UNIVERSITY   (United States)

Author keywords

Chemotherapy; Molecular imaging; Sindbis virus; Vascular leakiness; Viral vector

Indexed keywords

CISPLATIN; ONCOLYTIC VIRUS; PACLITAXEL; REPLICATION DEFICIENT ONCOLYTIC SINDBIS VIRUS VECTOR BETA GALACTOSIDASE; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENDOTHELIUM CELL; FEMALE; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PERITONEUM METASTASIS; PRIORITY JOURNAL; SINDBIS VIRUS; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL MEMBRANE PERMEABILITY; COMBINED MODALITY THERAPY; CRICETINAE; DRUG DELIVERY SYSTEMS; FEMALE; GENETIC VECTORS; HUMANS; MICE; MICE, SCID; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; ONCOLYTIC VIROTHERAPY; OVARIAN NEOPLASMS; PACLITAXEL; SINDBIS VIRUS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

SINDBIS VIRUS;

EID: 77949654870     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2009.70     Document Type: Article

References (49)

1. Iijima Y, Ohno K, Ikeda H, Sawai K, Levin B, Meruelo D. Cell-specific targeting of a thymidine kinase/ganciclovir gene therapy system using a recombinant Sindbis virus vector. Int J Cancer 1999; 80: 110-118.
2. Ohno K, Meruelo D. Retrovirus vectors displaying the IgG-binding domain of protein A. Biochem Mol Med 1997; 62: 123-127.
3. Ohno K, Sawai K, Iijima Y, Levin B, Meruelo D. Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A. Nat Biotechnol 1997; 15: 763-767.
4. Sawai K, Meruelo D. Cell-specific transfection of chorio-carcinoma cells by using Sindbis virus hCG expressing chimeric vector. Biochem Biophys Res Commun 1998; 248: 315-323.
5. Marcato P, Shmulevitz M, Lee PW. Connecting reovirus oncolysis and Ras signaling. Cell Cycle 2005; 4: 556-559.
6. O'Shea CC. Viruses\seeking and destroying the tumor program. Oncogene 2005; 24: 7640-7655.
7. Tseng JC, Levin B, Hurtado A, Yee H, Perez de Castro I, Jimenez M et al. Systemic tumor targeting and killing by Sindbis viral vectors. Nat Biotechnol 2004; 22: 70-77.
8. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-936.
9. Ribatti D, Nico B, Crivellato E, Vacca A. The structure of the vascular network of tumors. Cancer Lett 2007; 248: 18-23.
10. McDonald DM, Baluk P. Significance of blood vessel leakiness in cancer. Cancer Res 2002; 62: 5381-5385.
11. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci USA 1998; 95: 4607-4612.
12. Leunig M, Yuan F, Menger MD, Boucher Y, Goetz AE, Messmer K et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992; 52: 6553-6560.
13. Yuan F, Dellian M, Fukumura D, Leunig M, Berk DA, Torchilin VP et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995; 55: 3752-3756.
14. Liwnicz BH, Wu SZ, Tew Jr JM. The relationship between the capillary structure and hemorrhage in gliomas. J Neurosurg 1987; 66: 536-541.
15. Van den Brenk HA, Crowe M, Kelly H, Stone MG. The significance of free blood in liquid and solid tumours. Br J Exp Pathol 1977; 58: 147-159.
16. Tseng JC, Levin B, Hirano T, Yee H, Pampeno C, Meruelo D. In vivo antitumor activity of Sindbis viral vectors. J Natl Cancer Inst 2002; 94: 1790-1802.
17. Wang KS, Kuhn RJ, Strauss EG, Ou S, Strauss JH. High-affinity laminin receptor is a receptor for Sindbis virus in mammalian cells. J Virol 1992; 66: 4992-5001.
18. Ardini E, Pesole G, Tagliabue E, Magnifico A, Castronovo V, Sobel ME et al. The 67-kDa laminin receptor originated from a ribosomal protein that acquired a dual function during evolution. Mol Biol Evol 1998; 15: 1017-1025.
19. Menard S, Tagliabue E, Colnaghi MI. The 67 kDa laminin receptor as a prognostic factor in human cancer. Breast Cancer Res Treat 1998; 52: 137-145.
20. Griffin DE, Hardwick JM. Regulators of apoptosis on the road to persistent alphavirus infection. Annu Rev Microbiol 1997; 51: 565-592.
21. Griffin DE, Hardwick JM. Perspective: virus infections and the death of neurons. Trends Microbiol 1999; 7: 155-160.
22. Kerr DA, Larsen T, Cook SH, Fannjiang YR, Choi E, Griffin DE et al. BCL-2 and BAX protect adult mice from lethal Sindbis virus infection but do not protect spinal cord motor neurons or prevent paralysis. J Virol 2002; 76: 10393-10400.
23. Levine B, Huang Q, Isaacs JT, Reed JC, Griffin DE, Hardwick JM. Conversion of lytic to persistent alphavirus infection by the bcl-2 cellular oncogene. Nature 1993; 361: 739-742.
24. Bredenbeek PJ, Frolov I, Rice CM, Schlesinger S. Sindbis virus expression vectors: packaging of RNA replicons by using defective helper RNAs. J Virol 1993; 67: 6439-6446.
25. Tseng JC, Zanzonico PB, Levin B, Finn R, Larson SM, Meruelo D. Tumor-specific in vivo transfection with HSV-1 thymidine kinase gene using a Sindbis viral vector as a basis for prodrug ganciclovir activation and PET. J Nucl Med 2006; 47: 1136-1143.
26. Tseng JC, Daniels G, Meruelo D. Controlled propagation of replication-competent Sindbis viral vector using suicide gene strategy. Gene Therapy 2009; 16: 291-296.
27. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004; 4: 423-436.
28. Tseng JC, Hurtado A, Yee H, Levin B, Boivin C, Benet M et al. Using sindbis viral vectors for specific detection and suppression of advanced ovarian cancer in animal models. Cancer Res 2004; 64: 6684-6692.
29. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985.
30. Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli MR, Viale G et al. The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res 1996; 2: 1843-1849.
31. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 2003; 104: 121-129.
32. Ng SS, Figg WD, Sparreboom A. Taxane-mediated anti-angiogenesis in vitro: influence of formulation vehicles and binding proteins. Cancer Res 2004; 64: 821-824.
33. Pasquier E, Honore S, Pourroy B, Jordan MA, Lehmann M, Briand C et al. Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells. Cancer Res 2005; 65: 2433-2440.
34. Eliceiri BP, Paul R, Schwartzberg PL, Hood JD, Leng J, Cheresh DA. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 1999; 4: 915-924.
35. Brown LF, Dvorak AM, Dvorak HF. Leaky vessels, fibrin deposition, and fibrosis: a sequence of events common to solid tumors and to many other types of disease. Am Rev Respir Dis 1989; 140: 1104-1107.
36. Weis SM, Cheresh DA. Pathophysiological consequences of VEGF-induced vascular permeability. Nature 2005; 437: 497-504.
37. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat Med 2001; 7: 186-191.
38. Ferrara N. VEGF as a therapeutic target in cancer. Oncology 2005; 69(Suppl 3): 11-16.
39. Ong HT, Trejo TR, Pham LD, Oberg AL, Russell SJ, Peng KW. Intravascularly administered RGD-displaying measles viruses bind to and infect neovessel endothelial cells in vivo. Mol Ther 2009; 17: 1012-1021.
40. Liu TC, Castelo-Branco P, Rabkin SD, Martuza RL. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008; 16: 1041-1047.
41. Yoo JY, Kim JH, Kwon YG, Kim EC, Kim NK, Choi HJ et al. VEGF-specific short hairpin RNA-expressing oncolytic adenovirus elicits potent inhibition of angiogenesis and tumor growth. Mol Ther 2007; 15: 295-302.
42. Thorne SH, Tam BY, Kirn DH, Contag CH, Kuo CJ. Selective intratumoral amplification of an antiangiogenic vector by an oncolytic virus produces enhanced antivascular and anti-tumor efficacy. Mol Ther 2006; 13: 938-946.
43. Libertini S, Iacuzzo I, Perruolo G, Scala S, Ierano C, Franco R et al. Bevacizumab increases viral distribution in human anaplastic thyroid carcinoma xenografts and enhances the effects of E1A-defective adenovirus dl922-947. Clin Cancer Res 2008; 14: 6505-6514.
44. Mor F, Quintana FJ, Cohen IR. Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization. J Immunol 2004; 172: 4618-4623.
45. Lee CG, Link H, Baluk P, Homer RJ, Chapoval S, Bhandari V et al. Vascular endothelial growth factor (VEGF) induces remodeling and enhances TH2-mediated sensitization and inflammation in the lung. Nat Med 2004; 10: 1095-1103.
46. Kumar S, Gao L, Yeagy B, Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008; 10: 371-379.
47. Bertolini F, Paul S, Mancuso P, Monestiroli S, Gobbi A, Shaked Y et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003; 63: 4342-4346.
48. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000; 60: 1878-1886.
49. Shen DW, Fojo A, Chin JE, Roninson IB, Richert N, Pastan I et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986; 232: 643-645.